In Reply by Estilo, Cherry L. et al.
In Reply
CHERRY L. ESTILO,a CATHERINE VAN POZNAK,b JOSEPH M. HURYNa
aMemorial Sloan-Kettering Cancer Center, New York, New York, USA; bUniversity of Michigan
Comprehensive Cancer Center, Ann Arbor, Michigan, USA
Disclosure: The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and
free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the authors,
planners, independent peer reviewers, or staff managers.
The pathogenesis of osteonecrosis of the jaw (ONJ) re-
mains unknown. We share the interest in understanding the
role of antiangiogenic therapy in the etiology of
ONJ. Hence, the query of our clinical experience for poten-
tial risk factors for ONJ. However, our assessment of 74 pa-
tients treated with a range of antiangiogenic therapies and
i.v. bisphosphonates failed to show an association between
ONJ and the use of antiangiogenic agents [1], yet we iden-
tified two patients who developed ONJ following bevaci-
zumab therapy without prior use of a bisphosphonate [2].
The data are further confounded by the fact that most pa-
tients who receive antiangiogenic agents also receive
other chemotherapy drugs. Therefore, while the Aragon-
Ching data [3], as well as our own report [2], suggest a
potential role for antiangiogenic therapy in the develop-
ment of ONJ, one cannot fully conclude a definite asso-
ciation between antiangiogenic agents and ONJ. Clearly,
prospective studies with a large sample size are needed to
address risk. The upcoming ONJ registry trial, South-
west Oncology Group (SWOG) 0702, will prospectively
study 7,000 patients with metastatic bone disease treated
with zoledronic acid. SWOG 0702 takes a multidisci-
plinary approach to integrate both dental and oncology
data to address risk factors and incidence, as well as in-
vestigate correlatives to explore the mechanisms under-
lying ONJ. Data generated from SWOG 0702 and other
investigations will ultimately lead to a better understand-
ing of the risks and etiology of ONJ.
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